Agomab Therapeutics (AGMB) Cash & Equivalents (2024 - 2025)
Agomab Therapeutics (AGMB) posted quarterly Cash & Equivalents of $100.6 million for Q4 2025, down 45.1% year-over-year from $183.2 million in Q4 2024, and down 45.1% quarter-over-quarter from $183.2 million in Q4 2024.
Agomab Therapeutics (AGMB) Cash & Equivalents (2024 - 2025) Analysis & Trends
Agomab Therapeutics' Cash & Equivalents history runs 2 years deep, the most recent figure standing at $100.6 million for Q4 2025.
- In Q4 2025, Cash & Equivalents fell 45.1% year-over-year to $100.6 million; the TTM figure through Dec 2025 stood at $100.6 million (down 45.1% YoY), while the FY2025 annual figure was $100.6 million, down 45.79% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $100.6 million, down from $183.2 million in the prior quarter.
- The five-year high for Cash & Equivalents was $183.2 million in Q4 2024, with the low at $100.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Agomab Therapeutics | 7.07 Mn | -250.51 Mn | - | 257.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 100.59 Mn |
| Dec 31, 2024 | 183.22 Mn |